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Sir, We read the recent Brain publication by Saidha et al. (2011)
with great interest. In their manuscript, the authors suggested that
primary retinal pathology detectable by optical coherence tomog-
raphy (OCT) defines a subset of patients with multiple sclerosis
(Saidha et al., 2011). This subgroup of patients, which they
termed ‘macular thinning predominant phenotype’, was reported
to exist in 10% of the entire multiple sclerosis cohort examined
by spectral domain OCT (Cirrus) at the authors’ centres. The
macular thinning predominant OCT phenotype was defined by a
combination of average macular thickness below the 5th percent-
ile, with ipsilateral normal average retinal nerve fibre layer (RNFL)
thicknesses (between the 5th and 95th percentiles of RNFL values
from the manufacturer’s normative database), in one or both eyes,
in the absence of a history of acute optic neuritis in affected eyes
(Saidha et al., 2011). Sixty-two per cent (31/50) of patients ful-
filling the macular thinning predominant OCT criteria had a macu-
lar thickness below the 1st percentile. In addition, there was a
remarkable male preponderance among patients with the macular
thinning predominant phenotype (70% male versus 30% female),
a difference that was even more pronounced (77.4% male versus
22.6% female) among those patients with very low macular
thicknesses (51st percentile). These in vivo findings are in line
with a recent post-mortem analysis reporting retinal pathology in
multiple sclerosis beyond damage to the RNFL and the ganglion
cell layer (Green et al., 2010). These data are intriguing in that
they point to a novel concept of primary retinal damage in mul-
tiple sclerosis. They indicate that retinal pathology might not only
develop as a consequence of inflammatory attacks to the anterior
optic pathway causing retrograde axonal and neuronal degener-
ation with RNFL thinning and retinal ganglion cell loss, but that
the retina itself may be a primary target of degenerative or in-
flammatory processes. Together with a more rapid disease pro-
gression in the macular thinning predominant group reported by
Saidha et al. (2011), these findings would have substantial impact
not only on our understanding of multiple sclerosis disease
pathogenesis and heterogeneity, but also on patient counselling.
Therefore, independent confirmation or refutation of these results
is warranted.
Against this background, we analysed our datasets from a large
cohort of 370 patients with multiple sclerosis [262 relapsing remit-
ting multiple sclerosis, 61 secondary progressive multiple sclerosis,
36 primary progressive multiple sclerosis and 11 patients with
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clinically isolated syndrome, aged 42  12 years, 68/32%
female/male, disease duration 267  188 months, Expanded
Disability Status Scale (EDSS) median 2.5 (range 0.0–8.0)] and
71 healthy controls (age 33  10 years, 63/37% female/male),
investigated with a latest generation spectral domain OCT
system (Spectralis OCT) at three large academic multiple sclerosis
centres in Germany (Berlin, Du¨sseldorf, Hamburg) and examined
whether the proposed macular thinning predominant phenotype
and its frequency were also observed in our cohort. Patients had
been investigated by OCT during clinical studies or attended our
outpatient clinics for clinical assessment and counselling. When
plotting total macular volume against RNFL thickness (Fig. 1),
we were initially not able to visually discriminate the phenotype
described by Saidha et al. (2011) as a distinct subgroup of
patients. We would expect a macular thinning predominant
phenotype with primary retinal pathology to unmask itself in the
scatterplot as a distinct cluster. This was not the case in our data.
We did, however, identify 21 multiple sclerosis eyes from 17 pa-
tients [4.6% of our cohort, mean age 43  10 years, 10/7 female/
male, disease duration 285  152 months, EDSS median 2.5
(range 0.0–7.0)] with an RNFL thickness between the 5th
(88.2 mm) and the 95th percentile (118.5mm) and a total macular
volume below the 5th percentile (8.112 mm3), thus formally
fulfilling the macular thinning predominant phenotype definition
given by Saidha et al. (2011). Eight patients with relapsing remit-
ting multiple sclerosis were affected with one eye, three patients
with both eyes; five patients with primary progressive multiple
sclerosis were affected single sided, one patient in both eyes.
However, all eyes fulfilling the macular thinning predominant
phenotype definition were visually unambiguously located within
the general data distribution and did not stand out as outliers
(Fig. 1). Interestingly, 35.3% (6/17) of our patients fulfilling the
macular thinning predominant criteria were patients with primary
progressive multiple sclerosis, in contrast to Saidha et al. (2011),
who did not find the macular thinning predominant phenotype
among their primary progressive multiple sclerosis cohort, which
led to an exclusion of this subgroup. Four patients with primary
progressive multiple sclerosis also provided the four eyes below
the 1st percentile of the healthy control total macular volume.
Finally and important to note, our analysis revealed a frequency
of the macular thinning predominant phenotype in the control
group similar to the one we describe for our multiple sclerosis
cohort (five eyes from three control subjects; 3/71 = 4.2%).
Therefore, although we also found patients fulfilling the macular
thinning predominant phenotype definition, albeit at considerably
lower frequency than Saidha et al. (2011), our results do not
support the conclusion of a distinct macular thinning predominant
OCT phenotype in multiple sclerosis. Based on our observations in
a similarly sized cohort, which showed that eyes fulfilling macular
thinning predominant phenotype criteria are found in relapsing
remitting multiple sclerosis at a typical female to male ratio, in
primary progressive multiple sclerosis, and in healthy controls,
we assume that the respective data points are likely to represent
the margins of an otherwise normal distribution.
The results by Saidha et al. (2011) might have been influenced
by the a priori grouping of patients according to their position in
relation to an internal Cirrus OCT normative database, consisting
of 284 subjects with an age range of 18–84 years (mean age 46.5
years). As a consequence, this might imply distinct subtypes by
artificially clustering the outer bounds of normally distributed data,
when in reality, no clusters exist. Thus, a comparison of our scat-
terplot with that of Saidha et al. (2011) would be of interest.
On the other hand, technical and methodological differences
between our investigations and those of Saidha et al. (2011) re-
quire a cautious comparison and interpretation of the data. We
used a different spectral domain OCT device, Spectralis, which
measures macular volume using multiple repeats for single line
scans to reduce image noise, thus providing potentially better
imaging quality than the Cirrus OCT device used by Saidha
et al. (2011). Besides this difference in scanning technique, seg-
mentation algorithm differences might further influence results.
Patients displaying the macular thinning predominant phenotype,
when measured with Cirrus OCT, could be re-evaluated with
Spectralis OCT to determine whether differences in instruments
and scanning methodologies might be of importance.
Moreover, differences in patient cohorts may play a role. While
the study by Saidha et al. (2011) included American patients with
multiple sclerosis, our study comprised entirely German patients
with multiple sclerosis.
An intriguing finding by itself, however, is the retinal pathology
in multiple sclerosis, which stands independently of the existence
Figure 1 Scatterplot of total macular volume versus average
retinal nerve fibre layer thickness (RNFLT) of all eyes. The colour
depicts the diagnosis. The grey area represents the proposed
macular thinning predominant position. Solid black line = linear
regression analysis with R2 = 0.451; slashed lines = 95% confi-
dence intervals; dotted lines: 5th and 95th percentiles of RNFLT;
slashed/dotted line = 5th percentile of total macular volume.
CIS = clinically isolated syndrome; HC = healthy controls;
PPMS = primary progressive multiple sclerosis;
RRMS = relapsing remitting multiple sclerosis;
SPMS = secondary progressive multiple sclerosis.
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of the suggested macular thinning predominant phenotype detect-
able by OCT. For the Spectralis OCT, an intraretinal segmentation
algorithm is not yet available, and we were not able to provide
segmentation data, which is a clear methodological limitation of
our analysis. Thus, it will be of great interest to re-evaluate a
possible intraretinal pathology in our data when an algorithm be-
comes available.
In summary, although the OCT data on primary retinal path-
ology in multiple sclerosis are compelling, they require further in-
vestigation in order to clarify the discrepancies between our study
and that of Saidha et al. (2011). In particular, prospective studies,
which are designed and powered to investigate the existence and
the proportion of the postulated macular thinning predominant
phenotype in multiple sclerosis cohorts versus controls and a re-
consideration of the macular thinning predominant definition itself,
are necessary.
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